1. Home
  2. ABCL vs NUVB Comparison

ABCL vs NUVB Comparison

Compare ABCL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABCL
  • NUVB
  • Stock Information
  • Founded
  • ABCL 2012
  • NUVB 2018
  • Country
  • ABCL Canada
  • NUVB United States
  • Employees
  • ABCL N/A
  • NUVB N/A
  • Industry
  • ABCL Biotechnology: Pharmaceutical Preparations
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ABCL Health Care
  • NUVB Health Care
  • Exchange
  • ABCL Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • ABCL 772.9M
  • NUVB 679.9M
  • IPO Year
  • ABCL 2020
  • NUVB N/A
  • Fundamental
  • Price
  • ABCL $2.03
  • NUVB $2.10
  • Analyst Decision
  • ABCL Buy
  • NUVB Strong Buy
  • Analyst Count
  • ABCL 3
  • NUVB 5
  • Target Price
  • ABCL $7.50
  • NUVB $8.20
  • AVG Volume (30 Days)
  • ABCL 4.1M
  • NUVB 3.2M
  • Earning Date
  • ABCL 05-08-2025
  • NUVB 05-07-2025
  • Dividend Yield
  • ABCL N/A
  • NUVB N/A
  • EPS Growth
  • ABCL N/A
  • NUVB N/A
  • EPS
  • ABCL N/A
  • NUVB N/A
  • Revenue
  • ABCL $23,114,000.00
  • NUVB $10,957,000.00
  • Revenue This Year
  • ABCL N/A
  • NUVB $75.73
  • Revenue Next Year
  • ABCL $36.62
  • NUVB $440.21
  • P/E Ratio
  • ABCL N/A
  • NUVB N/A
  • Revenue Growth
  • ABCL N/A
  • NUVB N/A
  • 52 Week Low
  • ABCL $1.89
  • NUVB $1.54
  • 52 Week High
  • ABCL $4.34
  • NUVB $3.97
  • Technical
  • Relative Strength Index (RSI)
  • ABCL 34.87
  • NUVB 50.80
  • Support Level
  • ABCL $1.98
  • NUVB $1.98
  • Resistance Level
  • ABCL $2.64
  • NUVB $2.30
  • Average True Range (ATR)
  • ABCL 0.14
  • NUVB 0.16
  • MACD
  • ABCL -0.06
  • NUVB -0.01
  • Stochastic Oscillator
  • ABCL 7.14
  • NUVB 21.43

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Share on Social Networks: